Taiwan: National Taiwan University_a-fetoprotein as a indicator for therapeutic response of sorafenib, bevacizumab, or thalidomide in combination with

Cancer. 2010 Jun 22.
Early alpha-fetoprotein response predicts treatment efficacy of antiangiogenic systemic therapy in patients with advanced hepatocellular carcinoma.
http://www.ncbi.nlm.nih.gov:80/pubmed/20572033